XOMA

Xoma Royalty Corp

A biotechnology royalty company that buys the rights to future milestone and royalty payments from other drug developers, giving them cash to fund their research without selling more shares. Founded in 1981 as XOMA, it spent decades developing antibody drugs before pivoting in 2017 to become a royalty aggregator — and it was later folded into Ligand Pharmaceuticals. The name XOMA likely nods to the "-oma" suffix common in medical terminology for tumors, a fitting touch for a company born in the lab.